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Abstract 
While genetic variants have been reported to be associated with obsessive-compulsive 
disorder (OCD), the small effect sizes suggest that epigenetic mechanisms such as DNA 
methylation may also be relevant. The serotonin transporter (SLC6A4) gene has been 
extensively investigated in relation to OCD, since serotonin reuptake inhibitors are the 
pharmacological treatment of choice for the disorder. The current study set three questions: 
Firstly, whether the high expressing loci of the SLC6A4 polymorphisms, 5-
HTTLPR+rs25531, rs25532 and rs16965628 are associated with family-based (n=164 trios) 
and case-control OCD (n=186, 152, respectively). This was also examined by a meta-analysis. 
Secondly, whether DNA methylation and RNA levels of the SLC6A4 differ in saliva and 
blood of a subset of samples from pediatric and adult OCD patients and matched controls. 
And lastly, whether morning awakening cortisol levels correlate with the above. A meta-
analysis confirmed the association of the LA-allele with OCD (OR=1.21, p=0.00018), 
maintaining significance in the early-onset OCD subgroup (OR=1.21, p=0.022). There was no 
association between rs25532 or rs16965628 and OCD. Our preliminary data showed that 
SLC6A4 DNA methylation levels in an amplicon located at the beginning of the first intron 
were significantly higher in the saliva of pediatric OCD patients compared to controls and 
adult patients with OCD, but no alterations in RNA levels or in polymorphism interactions 
were observed. Morning awakening salivary cortisol levels positively correlated with 
methylation levels, and negatively correlated with RNA levels. This study further supports the 
involvement of the SLC6A4 gene in OCD through both genetic and epigenetic mechanisms. 
This finding needs to be explored further in an independent large sample. 
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Introduction 
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder, presenting with 
distressing, recurrent, persistent thoughts and compulsive, repetitive behaviors (American 
Psychiatric Association, 2013). The disease is present in both adults and children, affecting 
0.1 to 2.3% of the population (Ruscio et al., 2010; Wittchen et al., 2011). Despite strong 
heritability estimates from twin and family studies ranging between 40 and 80%, increasing 
proportionally to the degree of genetic relatedness (Mataix-Cols et al., 2013; Pauls et al., 
2014; van Grootheest et al., 2005), two recent genome-wide association studies (Mattheisen et 
al., 2014; Stewart et al., 2013) failed to detect genome-wide significances for single 
nucleotide polymorphisms (SNPs) in OCD. Indeed, it is postulated that both genetic and 
environmental factors may play an important role in the risk for OCD (Mataix-Cols et al., 
2013).  
The serotonergic system has been widely studied in relation to OCD, and selective 
serotonin reuptake inhibitors are the drug of choice for OCD treatment (Murphy et al., 2013). 
One of the genes most consistently associated with OCD is the serotonin transporter 
(SLC6A4) (Bloch et al., 2008; Dickel et al., 2007; Taylor, 2013; 2016). A polymorphism in 
the serotonin transporter-linked polymorphic region (5-HTTLPR) with a high-expressing L 
allele and a low-expressing S allele has been associated with OCD, with the L allele being the 
risk allele (Baca-Garcia et al., 2005; Bengel et al., 1999; McDougle et al., 1998). 
Nevertheless, several studies have failed to replicate this finding, partly because of sample 
size, but probably also due to the high variability in study design or patient samples (Atmaca 
et al., 2011; Billett et al., 1997; Camarena et al., 2001; Cengiz et al., 2015; Chabane et al., 
2004; Denys et al., 2006; Di Bella et al., 2002; Dickel et al., 2007; Frisch et al., 2000; Grados 
et al., 2007; Kim et al., 2005; Kinnear et al., 2000; Liu et al., 2011; Meira-Lima et al., 2004; 
Saiz et al., 2008; Walitza et al., 2004). Nonetheless, a meta-analysis demonstrated a 
significant association, albeit with a rather small effect size (Bloch et al., 2008; Dickel et al., 
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2007; Taylor, 2013; 2016). In 2006 Hu et al. described the presence of an additional SNP 
rs25531, within the 5-HTTLPR repetitive region (Hu et al., 2006). The G allele of rs25531 
was found to convert the L allele into a functionally S allele (Hu et al., 2006). This allows the 
division of the 5-HTTLPR modulated by rs25531 into a triallelic polymorphism: LA, which is 
high-expressing and LG and S (from here on referred to as S), which are low-expressing. The 
association of the triallelic 5-HTTLPR polymorphism with OCD risk has since been 
investigated in both adult and early-onset samples (Honda et al., 2017; Hu et al., 2006; 
Kenezloi et al., 2010; Moya et al., 2013; Rocha et al., 2009; Tibrewal et al., 2010; Tükel et al., 
2016; Voyiaziakis et al., 2011; Walitza et al., 2014; Wendland et al., 2007), in which a 
significant association of the LA allele has been confirmed by our group in a small meta-
analysis of OCD patients (Walitza et al., 2014). In addition, modulation of 5-HTTLPR 
functionality by the non-coding SLC6A4 polymorphisms rs25532 and rs16965628 has been 
demonstrated (Martin et al., 2007; Wendland et al., 2008). A haplotype containing the higher-
expressing allele at all three loci: the 5-HTTLPR triallelic polymorphism (LA), rs25532 (C) 
and rs16965628 (C) was found to be associated with higher OCD risk (Wendland et al., 
2008). Nevertheless, the following studies could not fully replicate this finding (Cengiz et al., 
2015; Kenezloi et al., 2010; Moya et al., 2013). 
Environmental factors, e.g. model learning, stress (e.g. stressful life events), trauma, 
are known to be important risk factors in the development of OCD (Faravelli et al., 2012; 
Gothelf et al., 2004; Morina et al., 2016) and are also known to modify gene transcription and 
expression. Furthermore, it was reported that perceived stress and basal cortisol levels were 
significantly higher in OCD patients than in controls (Morgado et al., 2013). Therefore, 
epigenetics is regarded as an important interface between environmental alterations causing 
changes in gene expression. Such epigenetic alterations regulate the accessibility for 
transcription factors and influence gene expression (Jaenisch & Bird, 2003). Epigenetic 
mechanisms may also play a role in the pathophysiology of OCD, as has already been 
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demonstrated in two preliminary genome-wide methylome analyses conducted in patients 
with OCD (Nissen et al., 2016; Yue et al., 2016). Nissen et al. (2016) reported in females with 
OCD differential methylation for GABBR1in blood samples at birth as well as for MOG and 
BDNF in blood samples at the time of diagnosis. Yue et al. (2016) found 8,417 probes 
corresponding to 2,190 genes being differentially methylated between OCD and healthy 
controls. Pathway analyses revealed that regulation of actin cytoskeleton, cell adhesion 
molecules, actin binding and transcription regulator activity pathways were involved. DNA 
methylation is one type of epigenetic modification that may affect gene transcription and 
consequently function. DNA methylation alterations of SLC6A4 in several psychiatric 
diseases as well as in behavioral adversities have been detected (Provenzi et al., 2016; 
Sugawara et al., 2013). However, the role of SLC6A4 epigenetic modifications in OCD is not 
yet clear. The focus of the present DNA methylation study will be on the SLC6A4 gene due to 
the repeatedly confirmed involvement of the serotonergic system in OCD and the fact that the 
serotonin transporter is the pathogenetic target of the first-line medications used for OCD 
treatment. 
In the current study we set out to re-investigate the association of the three high 
expressing loci of the SLC6A4 polymorphisms 5-HTTLPR+rs25531, rs25532 and rs16965628 
in early-onset family-based trios and case-control OCD, including a new meta-analysis 
covering current publications. Moreover, to investigate environmental effects on the genome, 
we compared DNA methylation levels of an amplicon located at the beginning of the first 
intron of SLC6A4 in blood and saliva samples of a subset of pediatric and adult OCD patients 
and demographically-matched controls as well as their peripheral whole blood gene 
expression profile. Lastly, we looked at the correlations between these parameters and 
morning awakening cortisol levels. 
Materials and Methods 
OCD patients and control samples 
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For the case-control study, 186 early-onset pediatric OCD patients and 164 child-
parent trios (465 individuals) were recruited at the Departments of Child and Adolescent 
Psychiatry of the Universities of Würzburg, Zurich (n=145 patients from Würzburg & 
Zurich), Marburg, Aachen, and Freiburg. One hundred and fifty-two healthy controls were 
recruited at the Departments of Child and Adolescent Psychiatry of the Universies of 
Würzburg and Zurich. The ethnicity of all participants was German or Swiss. Informed 
written consent was obtained in all cases from the participants or their parents. The study was 
approved by the ethical commissions of all involved universities in accordance with the latest 
version of the Declaration of Helsinki, including an ethical permission granted by the Ethic 
Committees from Aachen, Würzburg, Marburg, Freiburg, and the Cantonal Ethic Commission 
of Zürich (Ref. Nr. 39/97, 140/3 and EK: KEK-ZH-Nr. 2010-0340/3). Demographic 
characteristics of family and case-control study groups are summarized in Table 1 (for 
detailed inclusion and exclusion criteria see Supplementary methods). 
A sub-sample of participants was used for the SLC6A4 methylation (from saliva) and 
the gene expression (whole blood) and salivary cortisol levels consisting of four groups: 
pediatric OCD, adult OCD and their matching controls (part of a neuroimaging study 
described elsewhere (Hauser et al., 2017); for details see Supplementary methods and Table 
S1). Blood DNA methylation analysis was conducted using a collection of samples from an 
additional group of independent pediatric OCD patients. 
In line with the first aim of the present study, this was an extension and re-evaluation 
of a previously published significant association analysis with a transmission disequilibrium 
test (TDT) and meta-analysis of the 5-HTTLPR + rs25531 (triallelic) in OCD (Walitza et al., 
2014). The current study enlarged the family TDT sample (61 new cases and parents), added a 
case-control analysis and two additional SNPs (rs25532 and rs16965628), as well as a newly 
run meta-analysis with additional newly published data. 
DNA isolation from saliva and blood 
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The Oragene DNA collection kit was used for DNA isolation from saliva, following 
the manufacturer’s protocol (DNA Genotek; Canada). Following a previously described 
protocol for DNA isolation (Grünblatt et al., 2005), 2 ml of EDTA blood and proteinase K 
were used for DNA isolation from whole blood samples. DNA concentration, A260/A280 and 
A260/A230 ratios were measured with a NanoVue Plus spectrophotometer (GE Healthcare, 
Switzerland).  
Genotyping 
The restriction fragment length polymorphism method was used for the 5-HTTLPR 
triallelic (combined with the rs25531) polymorphism analysis (for detailed methods see 
Supplementary methods). The LA and LG alleles were distinguished based on the analysis of 
amplicon and restriction fragment sizes as previously described (Nyffeler et al., 2014; 
Wendland et al., 2006). Alleles were collapsed according to high functionality of La (labelled 
as L) versus low functionality of S or Lg (labelled as S). 
For the rs16965628 and rs25532 SNPs, genotyping was performed using TaqMan® 
SNP Genotyping Assays (Life Technologies, Switzerland; for details see Supplementary 
methods). 
Meta-analysis 
We conducted a systematic review using the preferred reporting items for systematic 
reviews and meta-analysis criteria (PRISMA) (Moher et al., 2009). Articles were searched to 
include studies that described association studies for SLC6A4 (HTTLPR+rs25531, 
rs16965628 & rs25532) in OCD (for details see Supplementary methods). The final search 
was undertaken on February 2nd 2017. A meta-analysis was conducted with the extracted data 
and the current study data using the MIX 2.0 Pro v.2.0.1.4 (BiostatXL, 2011. 
http://www.meta-analysis-made-easy.com). Variability due to between-study heterogeneity 
was estimated by I2 and funnel plots, publication bias using Begg’s and Egger’s regression 
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test (Begg & Mazumdar, 1994; Egger et al., 1997), and the quality of the studies was assessed 
based on traditional epidemiological considerations (Supplementary Figure S1 and Table S2). 
Bisulfite modification 
For the second study aim, the Universal Methylated Human DNA Standard (Zymo 
Research, CA, USA) was used as methylated human DNA standard. The unmethylated human 
control DNA (Qiagen) was used as unmethylated human DNA standard. 500 ng of genomic 
DNA from each sample (saliva or blood) and from the methylated/ unmethylated DNA 
controls was bisulfite converted with the EZ DNA Methylation-Gold Kit (Zymo Research), 
following the manufacturer’s instructions and using a final elution volume of 55 µl PCR grade 
water. 
Methylation sensitive-high resolution melting (MS-HRM) analysis and data quantification 
Astandard curve was constructed using bisulfite-converted artificially methylated 
(Zymo Research) and unmethylated DNA (Qiagen) in different dilutions to acquire 0%, 0,1%, 
0.5%, 1%, 5%, and 100% standards. The following primers were used for MS-HRM: SLC6A4 
forward primer - CGAGGAGGCGAGGAGGTGT; SLC6A4 reverse primer – 
CGTTCCTCGTCTCCCACTCTAA (for chromosomal location and CpG sites see Suppl. 
Figure S2). Methylation sensitive-high resolution melting experiments were carried out with 
the LightCycler 480 High Resolution Melting Master mix (Roche Diagnostics Schweiz AG, 
Switzerland), 250 nM primers and 1.5 µl of the bisulfite converted DNA, 2.5 mM Mg and 
water to complete the required volume. PCR and preliminary analysis of the data was 
conducted on the CFX96 real-time Thermal Cycler (Bio-Rad) and the Precision MeltAnalysis 
Software v1.2 (BioRad). For quantification of the data, a polyfit interpolating model in 
Matlab® v.8.6 (Math Works) was used, according to a previously published protocol and 
algorithm obtained by the authors (Migheli et al., 2013).  
Total RNA extraction and quantitative real-time RT-PCR 
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Whole blood was collected with the PAXgene™ Blood RNA system (Becton 
Dickinson GmbH, Heidelberg, Germany), and total RNA was extracted using the PAXgene™ 
Blood RNA Kit 50 (PreAnalytiX, Qiagen and BD, Germany). Quantitative real-time RT-PCR 
was conducted for SLC6A4 (QT00058380) gene and six additional reference genes (ACTB- 
QT00095431, GAPDH- QT00079247, ALAS1- QT00073122, RPL13A- QT00089915, PPIA- 
QT00052311, and 18S ribosomal RNA- QT00199367) as described previously (Grünblatt et 
al., 2009) (for further details see Supplementary methods). Gene expression and 
normalization analysis with the most stable reference genes was conducted using the 
qBasePLUS v.2.3 (Biogazelle) (Vandesompele et al., 2002). 
Salivary free cortisol levels 
For the third aim, investigating correlations between the aforementioned parameters 
and cortisol levels, we analyzed a sub-set of the salivary cortisol levels at morning wake-up 
time. Active free cortisol in saliva was measured in samples collected at baseline (directly 
after wake-up time; expected cortisol values 1-11-3 ng/ml 5-95% percentile). Cortisol levels 
were measured with cortisol free in saliva ELISA (DES6611, Demeditec Diagnostics GmbH, 
Germany) following the manufacturer’s protocol (for further details see Supplementary 
methods). 
Statistical analysis 
All association studies were run on the PLINK v1.7 (URL: 
http://pngu.mgh.harvard.edu/purcell/plink/ (Purcell et al., 2007)). Each study group (case-
control study) was tested for Hardy-Weinberg equilibrium (HWE) (Suppl. Table S3). For the 
case-control association study, the Fisher’s Exact Test was conducted and significance was set 
at p<0.017 for multiple testing. For the family association study, Mendel errors test (none 
were found) followed by the transmission disequilibrium test (TDT) was conducted as well as 
a parent-of-origin analysis.  
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Statistical analysis was carried out with SPSS v23 (IBM) and SAS 9.4. To test the 
normality of the DNA methylation levels distribution, the Komogorov-Smirnov and Shapiro-
Wilk tests were used. To ensure consistency, non-parametric assessments were carried out 
throughout the manuscript. The Mann-Whitney test was used for comparisons between two 
groups and the Kruskal-Wallis H test for comparisons between more than two groups. To 
control for possible confounding factors for SLC6A4 methylation levels (i.e. gender, age, 
groups: pediatric OCD and their respective controls, and SSRI medication), an ANCOVA was 
conducted. This analysis was only conducted for the pediatric OCD group as the group size 
was too small in the adults to concurrently test for multiple confounders. A model containing 
only main effects was used. Assumptions for the ANCOVA were tested by visual inspection 
of standardized residuals versus predicted plot in order to rule out heteroscedasticity. 
Observations with standardized residuals higher than 3 or below -3 were excluded from the 
analysis. This led to the exclusion of one participant. Spearman’s rank test was used for 
continuous variables correlations. Statistical corrections for multiple comparisons were not 
conducted due to the  explorative nature of this study in which the objective was the 
generation of a new hypothesis for epigenetics in OCD. 
Results 
SLC6A4 promoter polymorphisms association in early-onset pediatric OCD 
In the case-control association study there were no significant associations between 5-
HTTLPR+rs25531, rs16965628 and rs25532 and early-onset pediatric OCD, shown in Table 
2. Similarly, in the family-based TDT association study we did not observe a significant 
transmission of the SLC6A4 polymorphism alleles in our OCD-affected child-parent trios 
(Table 3). However, in rs25532 we observed a nominally significant p-value (0.0455) for 
paternal under-transmission of the minor T-allele (Table 3). Haplotype association analysis 
(see detailed results in supplementary results Table S6 & S7), resulted in a nominal significant 
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haplotype H4 (LA;T) of the 5-HTTLPR+rs25531 and rs25532 (p=0.031), while no significant 
association was found for the three-locus haplotype and early-onset OCD.  
Meta-analysis for SLC6A4 promoter polymorphism in OCD 
In order to evaluate the association of the studied SLC6A4 promoter polymorphism 
with OCD, we included the current data of the case-control and TDT study in a meta-analysis 
of all published studies (Fig. 1). For 5-HTTLPR+rs25531 we could include three new 
publications of adult OCD from Turkey (Tükel et al., 2016), pediatric OCD from Hungary 
(Kenezloi et al., 2010), and adult OCD Brazilian-Caucasian (Rocha et al., 2009), together 
with our new case-control and the enlarged TDT sample of the previously published study 
(Walitza et al., 2014). We excluded a study reporting genetic association between 5-
HTTLPR+rs25531 and rs25532 of adult Tourette patients comorbid with OCD (Moya et al., 
2013), since DSM-5 differentiates between Tourette and OCD. A study of adult OCD and 5-
HTTLPR+rs25531 by Honda et al. (Honda et al., 2017) was also excluded, as it deviated from 
all other studies causing an increase in heterogeneity (I2). It also demonstrated low quality 
scores and was the only Asian ethnicity (see supplementary Table S2). We observed a 
significant meta-analysis p-value of 0.00018 for association of the LA allele with OCD (total 
n=5026, cases n= 1972, OR = 1.2104, 95% confidence interval (CI) 1.095–1.338, Fig. 1A). 
We further stratified the meta-analysis by age of onset, as this was thought to be an important 
variable in association studies (Mattina & Steiner, 2016), only running the analysis for early-
onset pediatric OCD publications. This analysis demonstrated a significant association 
between the LA allele with early-onset OCD (total n=2944, cases n= 1086, OR = 1.207, 95% 
CI 1.027–1.418, p-value = 0.022, Fig. 1B). For rs16965628 (3 studies (Cengiz et al., 2015; 
Kenezloi et al., 2010; Wendland et al., 2008) + current TDT and case-control) and rs25532 (2 
studies (Kenezloi et al., 2010; Wendland et al., 2008) + current TDT and case-control), there 
was no significant meta-analysis association between OCD and the C allele or T allele, 
respectively (rs16965628: total n=2251, cases n= 827, OR = 0.846, 95% CI 0.527–1.357, p-
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value = 0.487, Fig. 1C; rs25532: total n=2075, cases n= 747, OR = 0.798, 95% CI 0.624–
1.02, p-value = 0.072, Fig. 1D). Moreover, we observed a significantly high heterogeneity for 
rs16965628 (supplementary Table S2). 
SLC6A4 DNA methylation and gene-expression of pediatric- and adult-OCD patients and 
healthy controls 
The subset population in which DNA and RNA was collected for SLC6A4 DNA 
methylation and gene expression levels consisted of pediatric OCD patients with age and 
gender matched controls and adult OCD patients with age and gender matched adult controls 
(Suppl. Table S1). The gender ratio, age, age of onset and (C)Y-BOCS scores (for the OCD 
groups) were significantly different between the pediatric and adult groups (more female 
F/M=10/8 adult vs. 12/32 saliva pediatric, 20 years older, higher age of onset 15.98±1.76 
years in adults vs. 9.94±0.47 years in saliva pediatric and lower Y-BOCS in adult group 
16.4±2.56 vs. CY-BOCS 23.34±1.0 in saliva pediatric OCD).  
SLC6A4 methylation levels were significantly higher (1.6 x of pediatric control) in 
early-onset pediatric OCD patients compared to healthy pediatric controls as demonstrated by 
a Mann-Whitney test (p < 0.05) (Fig. 2A). Furthermore, methylation levels were significantly 
lower in adult OCD compared both to adult controls (36% of adult controls) and pediatric 
OCD samples (21% of pediatric OCD; Fig. 2A). To investigate whether both saliva and blood 
tissue served as a source of DNA methylation biomarker, we compared methylation levels 
between two independent pediatric OCD groups in which DNA was isolated from either 
saliva or blood. The SLC6A4 DNA methylation levels were significantly lower in the blood 
sample compared to the saliva group (Mann-Whitney test, p < 0.05). Furthermore, there was a 
negative correlation between SLC6A4 DNA methylation levels in the saliva of pediatric OCD 
patients and OCD symptom severity as measured by the CY-BOCS (rs(42) = -0.380, p = 
0.013) as well as with the age of patients at the time of assessment (rs(42) = -0.358, p = 0.02) 
(Suppl. Table S4). There were no significant correlations between the SLC6A4 methylation 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
levels in the blood of pediatric OCD patients and any of the parameters. Furthermore, there 
were no significant correlations between SLC6A4 methylation levels in the saliva of pediatric 
control participants and any of the parameters (Suppl. Table S4). Methylation levels of 
SLC6A4 were significantly higher in pediatric female controls compared to males (m (32): 
0.058 ± 0.062% f (20): 0.099 ±0.066%, p<0.05). No methylation differences were observed 
between males and females in the saliva or blood of pediatric OCD patients (supplementary 
Table S1). Since gender, age, and SSRI medication may play a role in SLC6A4 methylation 
levels, these parameters were included as confounders in an ANCOVA analysis. This analysis 
demonstrated significantly higher methylation levels in children and adolescents with OCD 
compared to healthy controls, with age and gender as confounders, while SSRI treatment 
resulted in a non-significant effect on SLC6A4 methylation levels (F(1,83)=0.03, p=0.8558). 
When this last parameter was omitted from the ANCOVA analysis, age (F(1,84)=5.17, 
p=0.025; increasing age within 1 year causes decrease in methylation of 0.0059), gender 
(F(1,84)=10.51, p=0.0017; females gender increase methylation of 0.051), and group 
(F(1,84)=5.41, p=0.0224; pediatric OCD group increase methylation of 0.035) had a 
significant effect on the methylation levels.  
There were no significant alterations in SLC6A4 gene expression levels between the 
four groups (Fig. 2B). SLC6A4 mRNA levels did not correlate with salivary SLC6A4 DNA 
methylation levels (Suppl. Table S5). 
SLC6A4 DNA methylation, mRNA and salivary cortisol levels of pediatric- and adult-OCD 
patients and healthy controls 
Morning awakening salivary cortisol measurements were taken in the subset-
population to allow for the measurement of concomitantly salivary SLC6A4 DNA methylation 
and blood gene expression (total n= 61; see Suppl. Table S1). Morning cortisol levels in both 
pediatric and adult OCD patients were significantly lower than in age matched controls 
(Suppl. Table S1). Since cortisol levels are suggested to influence DNA methylation, a 
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correlation analysis was conducted. A correlation analysis of the complete sample of controls 
and OCD demonstrated a positive correlation between SLC6A4 DNA methylation levels and 
morning salivary cortisol levels (rs(41) = 0.323, p = 0.039) (Suppl. Table S5). 
Discussion 
The current study was able to confirm and strengthen the association between the 
refined 5-HTTLPR+rs25531 polymorphism and OCD as well as demonstrating its association 
in the stratified analysis of early-onset pediatric OCD. However, we were not able to find an 
association between the two other SNPs on the SLC6A4 gene and OCD, even after a meta-
analysis. Since Hu and colleagues (Hu et al., 2006) described the refined 5-HTTLPR 
polymorphism, several meta-analyses have been conducted, with some finding an association 
with OCD (Dickel et al., 2007; Taylor, 2013; 2016; Walitza et al., 2014) whilst others have 
not (Bloch et al., 2008; Lin, 2007; Mak et al., 2015). These inconsistencies are most likely to 
have arisen from some studies only analyzing the 5-HTTLPR polymorphism without the 
modification of the rs25531 or in combination with the refined 5-HTTLPR+rs25531 
polymorphism. Indeed, as discussed previously, age of onset and gender seem to play a role in 
genetic association in OCD (Mattina et al., 2016), as our stratified analysis of 5-
HTTLPR+rs25531 demonstrated a significant association with early-onset OCD. For the two 
additional SNPs, since heterogeneity was rather large, a larger and more homogenous sample 
would be required to prove or reject the association.  
After finding that the 5-HTTLPR+rs25531 played a role in the risk of OCD, we tested 
whether SLC6A4 DNA methylation levels were altered in OCD patients. Our preliminary data 
suggested increased DNA methylation levels of the SLC6A4 in the saliva of children and 
adolescents with OCD, while the opposite seemed to occur in adult OCD patients. Since a 
previous publication, which analyzed DNA methylation of the SLC6A4 promoter, found 
similar alterations in the saliva and blood as a consequence of a stress test (Nikolova et al., 
2014), we tested whether SLC6A4 DNA methylation levels in pediatric OCD in blood are 
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similar to those in saliva. Although both groups (saliva and blood) were age, age of onset and 
sex matched, we did not find similar methylation levels, which might be due to the fact that 
the saliva and blood samples were not collected from the same individuals. This is in contrast 
to the findings of Smith et al. (2015), in which the cg03363743 (within the current MS-HRM 
analysis) was found to correlate significantly between blood and saliva from the sample 
participants (R2=0.775, t=6.5, p=5.19E-8). Tissue methylation specificity is supported by the 
data from the Complex Disease Epigenetics Group, as observed for the CpG site cg03363743, 
included in our MS-HRM analysis (Suppl. Figure S2), with DNA methylation of around 30% 
for prefrontal cortex, entorhinal cortex, superior temporal gyrus, and blood, while low in 
cerebellum (ca. 15%) (Extracted from the Complex Disease Epigenetics Group (Hannon et 
al., 2015), http://epigenetics.iop.kcl.ac.uk/bloodbrain/?probenameg=Cg03363743). However, 
during brain development, the methylation levels for the CpG site cg03363743 seems to vary 
between 0.5 to 35% ((Spiers et al., 2015) http://epigenetics.essex.ac.uk/fetalbrain2/). Such 
variations were also observed in a recent study measuring SLC6A4 promoter methylation 
levels in whole blood, saliva and buccal cells with methylation of 0% up to 14% (Ismaylova 
et al., 2017). 
We found that age correlated with decreasing SLC6A4 DNA methylation levels 
(Suppl. Table S4). Moreover, medication, in particular SSRI’s, may cause methylation 
alteration, since the serotonin transporter is the pathogenetic target of the first-line medication 
used for OCD treatment. For example, lower DNA methylation in the SLC6A4 gene region, 
responsible for transcriptional control upstream of exon 1A, has been associated with an 
impaired therapeutic response to the antidepressant citalopram (Domschke et al., 2014). 
Okada and colleagues (Okada et al., 2014) demonstrated that a treatment with antidepressants 
of Japanese patients with a major depressive disorder (treated with paroxetine, fluvoxamine, 
or milnaciprane for 6 weeks) resulted in an increase in DNA methylation levels (in blood) of 
CpG site 3 of their amplicon in the promoter region of SLC6A4, as well as correlating with the 
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improvement ratio. Taking age, gender, and medication (SSRIs) as confounders, resulted in a 
significantly higher methylation level in pediatric OCD compared to matched controls. This, 
however, was not due to SSRI medication; there was an interaction with age and gender.  
Some evidence for cortisol levels and SLC6A4 promoter DNA methylation levels 
correlation has been reported (Alexander et al., 2014; Ouellet-Morin et al., 2013). In the 
current study, morning awakening salivary cortisol levels positively correlated with salivary 
SLC6A4 DNA methylation levels (Suppl. Table S5). Moreover, morning salivary cortisol 
levels were lower in OCD patients compared to the matched control group (Suppl. Table S1). 
A lower morning basal salivary cortisol level was observed in healthy children having high 
daily perceived stress (Maldonado et al., 2008) as well as in, for instance, emergency 
department nurses reporting higher stress at work compared to general ward nurses (Yang et 
al., 2001). Perceived stress leading to lower morning salivary levels might be a sign of 
chronic stress, which is hypothesized to be a risk factor for OCD development (Faravelli et 
al., 2012; Gothelf et al., 2004; Morgado et al., 2013; Morina et al., 2016). 
Lastly, the combination and interaction of genetic and epigenetic effects may play an 
important role in the risk of vulnerability to psychiatric disorders. Therefore, we determined 
SLC6A4 DNA methylation levels as a function of the genotypes at the 5-HTTLPR triallelic 
polymorphism, rs25532 and rs16965628 (Suppl. Results Fig. S3). We did not detect 
statistically significant differences in DNA methylation levels depending on the investigated 
genotypes. However, due to the relatively small sample size of our study, such methylation 
alterations need to be investigated in a larger study group. A previous study also failed to find 
an association between the 5-HTTLPR triallelic polymorphism and SLC6A4 DNA 
methylation (Domschke et al., 2014). However, the association between genotype and DNA 
methylation could be more complex or dependent on the particular promoter region studied 
(Vijayendran et al., 2012). 
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In summary, our pilot study demonstrated an increase in the SLC6A4 promoter DNA 
methylation levels in the saliva of children and adolescents with OCD. DNA methylation 
provides one important epigenetic mechanism through which environmental influences can 
affect psychiatric disease risk. Further replications of these data on independent study cohorts 
are warranted in order to elucidate the potential role of DNA methylation in OCD. 
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Figure Legends 
Figure 1. Summary and meta-analysis of all published association analyses of the serotonin 
transporter 5-HTTLPR+rs25531, rs16965628 and rs25532 with obsessive–compulsive 
disorder (OCD). (A) forest plot for 5-HTTLPR+rs25531 gain-of-function LA allele versus 
LG+S allele in OCD. (B) forest plot for 5-HTTLPR+rs25531 gain-of-function LA allele versus 
LG+S allele in early-onset pediatric OCD. (C) forest plot for rs16965628 C allele versus G 
allele in OCD. (D) forest plot for rs25532 T allele versus C allele in OCD. Black whiskers in 
the forest plot represent 95% confidence intervals (CI) for odds ratio; the sample size is 
reflected in symbol size. Sample demographics and study quality was summarized in Suppl. 
Table S2. Abbreviations: CC, case–control; TDT, transmission disequilibrium test; FBAT, 
family-based association testing. 
 
Figure 2. SLC6A4 DNA methylation in saliva and gene expression in whole blood of early-
onset pediatric obsessive-compulsive disorder (OCD) patients, pediatric healthy controls, 
adult OCD and adult healthy controls. A. DNA methylation levels in saliva, presented as 
mean ± SEM. B. Gene expression levels in whole blood RNA samples, presented as mean ± 
SEM. Normalization of SLC6A4 mRNA was conducted using qBasePLUS v.2.3 with the four 
reference genes: ACTB, GAPDH, ALAS1 and RPL13A. Kruskal-Wallis test followed by 
Mann-Whitney Test * p<0.05 vs. saliva pediatric control; ** p<0.05 vs. saliva pediatric OCD; 
+ p<0.05 vs. saliva adult control 
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Table 1. Demographic characteristics for the pediatric OCD and control subjects used for the 
case-control and the pediatric OCD patients of the family-trio study.  
 Case-control study Family-trio study 
Control Pediatric OCD Pediatric OCD 
N 152 186 164 
Gender Male 87 116 100 
Female 65 70 64 
Age (years, Mean ± SD) 11.77 ± 3.02 13.07 ± 2.83 * 12.79 ± 2.85 
Age of onset (years, Mean ± 
SD) 
n.a. 10.70 ± 3.12a 10.696 ± 3.19 
CY-BOCS (Score, Mean ± 
SD) 
n.a. 22.78 ± 7.14 22.38 ± 7.10 
IQ (Score, Mean ± SD) 111.53 ± 13.29 108.71 ± 15.0 108.11 ± 13.9 
Chi2-Test for nominal data; Kruskal-Wallis Test followed by Mann-Whitney Test * p<0.05 
was considered significant. Abbreviation: n.a., not available. a Age of onset of pediatric OCD 
was not significantly different from the age of controls. 
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Table 2. Case-control association analysis of SLC6A4 promoter polymorphism in pediatric 
OCD. 
CHR SNP BP A1 F_A F_U A2 P OR SE L95 U95 
17 rs16965628 30228407 C 0.06216 0.07432 G 0.5388 0.8255 0.309 0.4505 1.513 
17 rs25532 30237152 T 0.1189 0.1689 C 0.0733 0.664 0.2233 0.4287 1.029 
17 HTTLPR+rs25531 30237328 S+LG 0.4375 0.4671 LA 0.4834 0.8873 0.1557 0.6539 1.204 
Fisher’s exact test (allelic association). 
Abbreviations, BP, physical position (base-pair); A1, minor allele name; F_A, Frequency of 
minor allele in cases; F_U, frequency of minor allele in controls; A2, major allele name; P- 
exact p-value for this test; OR, estimated odds ratio (for A1); SE, standard error; L95, lower 
bound of 95% confidence interval for odds ratio; U95, upper bound of 95% confidence 
interval for odds ratio 
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Table 3. Transmission disequilibrium test for association of SLC6A4 promoter polymorphism in pediatric OCD 
CHR SNP BP A1:A2 T U OR L95 U95 CHISQ P T:U_PAT CHISQ_PAT P_PAT T:U_MAT CHISQ_MAT P_MAT Z_POO P_POO 
17 rs16965628 30228407 C:G 15 21 0.7143 0.3682 1.386 1 0.3173 07:10 0.5294 0.4669 08:11 0.4737 0.4913 -0.05643 0.955 
17 rs25532 30237152 T:C 24 37 0.6486 0.3881 1.084 2.77 0.09602 12:24 4 0.0455 12:13 0.04 0.8415 -1.148 0.251 
17 HTTLPR+rs25531 30237328 S+LG:LA 55 73 0.7534 0.531 1.069 2.531 0.1116 25.5:35.5 1.639 0.2004 29.5:37.5 0.9552 0.3284 -0.2541 0.7994 
Abbreviations: BP, physical position (base-pair); A1, minor allele name; A2, major allele name; T, transmitted minor allele count, U, untransmitted 
allele count; OR, TDT odds ratio; L95, lower bound of 95% confidence interval for odds ratio; U95, upper bound of 95% confidence interval for 
odds ratio; CHISQ, TDT chi-square statistic; P, TDT asymptotic p-value; T:U_PAT, Paternal transmitted : untransmitted counts; CHISQ_PAT, 
paternal chi-squared test; P_PAT, paternal asymptotic p-value; T:U_MAT, maternal transmitted : untransmitted counts; CHISQ_MAT, maternal 
chi-squared test; P_MAT, maternal asymptotic p-value; Z_POO, Z score for difference in paternal versus maternal odds ratios; P_POO, asymptotic 
p-value for paternal-of origin test; Bold, Nominal significance p<0.05. 
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